Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - DRUGS.COM - Clinical Trials News - 10/Jul 22:07
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
SYDNEY, July 10, 2024. Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients...
Articles similaires
Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome
pharmabiz.com - 04/Sep 00:00
Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...
Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
drugs.com - 08/Sep 06:09
September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...
Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
drugs.com - 08/Sep 06:09
September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...
First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
drugs.com - 09/Sep 20:09
HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...
Neurotech’s cannabinoid drug reverses immune dysregulation in PANDAS/PANS kids
stockhead.com.au - 09/Sep 04:15
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
Neurotech’s cannabinoid drug reverses immune dysregulation in PANDAS/PANS kids
stockhead.com.au - 09/Sep 04:15
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Les derniers communiqués
-
Adobe Brings Conversational AI to Trillions of PDFs with the New AI Assistant in Reader and Acrobat
Adobe - 21/02/2024
-
Laura Frigenti takes the Helm as Chief Executive Officer of the Global Partnership for Education
Global Partnership for Education - 05/12/2022